POSTMARKETING DRUG SURVEILLANCE - DATA PRESENTATION AND ELEMENTS FOR A DECISION

被引：0

|

作者：

LAGIER, G

机构：

来源：

REVUE DE MEDECINE INTERNE | 1986年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：41 / 44

页数：4

相关论文

共 50 条

[1] POSTMARKETING DRUG SURVEILLANCE
FELDMANN, EG
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (12) : R1 - R1
[2] POSTMARKETING DRUG SURVEILLANCE
BORDEN, EK
GARDNER, JS
WESTLAND, MM
GARDNER, SD
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (06): : 729 - 729
[3] THE IMPORTANCE OF POSTMARKETING DRUG SURVEILLANCE
SMART, AJ
WALTERS, L
[J]. SOUTH AFRICAN MEDICAL JOURNAL, 1992, 82 (06): : 383 - 384
[4] Postmarketing surveillance for drug abuse
Arfken, CL
Cicero, TJ
[J]. DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) : S97 - S105
[5] WORLDWIDE POSTMARKETING DRUG SURVEILLANCE
VENULET, J
[J]. REVUE DE MEDECINE INTERNE, 1986, : 52 - 56
[6] Postmarketing surveillance for drug safety
Holden, WL
Scarazzini, LJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 503 - 503
[7] POSTMARKETING DRUG SURVEILLANCE STUDIES
FAICH, GA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (05) : 597 - 597
[8] USE OF MEDICAID DRUG-EVENT DATA FOR POSTMARKETING SURVEILLANCE
JONES, JK
RUSKIN, A
MORSE, L
LEROY, A
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 256 - 256
[9] Using drug courts for drug postmarketing surveillance
Griffin, O. Hayden, III
Woodward, Vanessa H.
[J]. DRUGS AND ALCOHOL TODAY, 2016, 16 (02) : 165 - 175
[10] DATA QUALITY IN POSTMARKETING SURVEILLANCE
GIRARD, M
[J]. ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS, 1986, 5 (02): : 87 - 95

← 1 2 3 4 5 →